Nurix Therapeutics (NRIX) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nurix Therapeutics (NRIX) has outperformed Vera Therapeutics (VERA) over the past year, gaining 122.5% versus a loss of 2.5%. Over five years, VERA leads with a +98.1% price change compared with -23.0% for NRIX. Nurix Therapeutics is the larger company by market cap ($2.30 billion vs $2.14 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRIX | VERA |
|---|---|---|
| Share price | $22.21 | $29.73 |
| Market cap | $2.30B | $2.14B |
| 1-day change | -2.29% | -1.72% |
| YTD return | +17.08% | -41.29% |
| 1-year return | +122.55% | -2.52% |
| 5-year return | -22.96% | +98.07% |
| EPS (TTM) | $-3.46 | $-5.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.23 | $56.05 |
| 52-week low | $9.00 | $23.05 |
| Distance from 52-week high | -21.32% | -46.96% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +52.77% | +160.68% |
| Average volume | 1.27M | 2.21M |
| Shares outstanding | 103.78M | 72.06M |
| Employees | 317 | 361 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRIX has outperformed VERA by 125.1 percentage points over the past year.
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
NRIX vs VERA FAQ
Which is bigger, Nurix Therapeutics or Vera Therapeutics?
Nurix Therapeutics (NRIX) is larger, with a market capitalization of $2.30B compared with $2.14B for Vera Therapeutics (VERA).
Which stock has performed better over the past year, NRIX or VERA?
NRIX returned +122.55% over the past 12 months, compared with -2.52% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are Nurix Therapeutics and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.